Investigational drug · Phase 2
NXC736
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alopecia Areata.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NXC736"
First trial start
2024
Sep 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NXC736", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alopecia Areata
Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "NXC736" as an intervention, largest first.
- Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia AreataRecruiting
NEXTGEN BioscienceIndustry
NCT06104839 · 73 participants (planned) · Start Sep 1, 2024 · Primary completion Oct 31, 2026
Drug: NXC736; Placebo · For: Alopecia Areata
Sites: Seoul, South Korea · 2 sites in all
- A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy ParticipantsCompleted
NEXTGEN BioscienceIndustry
NCT05079425 · 72 participants · Start Sep 1, 2021 · Primary completion Nov 1, 2022
Drug: NXC736; Placebo · For: Healthy
Sites: Seoul, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine-1-phosphate receptor modulator.
Chung WK, Kim H, Park Y, et al. · Br J Clin Pharmacol 2026
- Blocking S1P4 signaling attenuates brain injury in mice with ischemic stroke.
Basnet N, Cho H, Sapkota A, et al. · J Adv Res 2025
- NXC736, a Functional Antagonist of S1P4, Attenuates Brain Injury in Mice with Permanent Ischemic Stroke.
Basnet N, Tiwari S, Choi KH, et al. · Molecules 2025
- NXC736 Attenuates Radiation-Induced Lung Fibrosis via Regulating NLRP3/IL-1β Signaling Pathway.
Kim SY, Park S, Cui R, et al. · Int J Mol Sci 2023
Also in development for Alopecia Areata
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- CTP-543Phase 31 trial
Sun Pharmaceutical Industries, Inc. · Alopecia Areata
- ADX-914bempikibartPhase 22 trials
Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- LAD603Phase 21 trial
Almirall, S.A. · Alopecia Areata
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.